SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BioInvent Reports 24% Response Rate for BI-1808 Plus Keytruda

Updated Part B data showed a 24% objective response rate among 34 evaluable patients with platinum-resistant ovarian cancer. Tolerability was described as favorable; a randomized Part C trial is expected to start in Q1 2027.

BINV
SquawkNews Desk

Related stories

Microsoft Says Consumer Services Recovered, Enterprise Recovery Ongoing Microsoft said its consumer products services had fully recovered at 4:10 p.m. UTC Friday, while Microsoft 365 enterprise services were seeing some sustained recovery. The company M impact | EQUITY | Nov 14, 2026, 05:32 AM UTC Microsoft Says Consumer Products Services Recovered Microsoft said its consumer products services had fully recovered, while Microsoft 365 enterprise services were seeing a sustained recovery. M impact | EQUITY | Nov 14, 2026, 05:17 AM UTC Microsoft restores consumer product services after outage Microsoft said its consumer product services have been restored; other services are not included in the update. M impact | EQUITY | Nov 14, 2026, 05:10 AM UTC Microsoft Outlook Begins Returning After Global Microsoft 365 Disruption Microsoft said it was working to restore email access after a global Microsoft 365 disruption. Industry executives warned of risks from dependence on a single technology provider. M impact | EQUITY | Nov 14, 2026, 04:31 AM UTC Tesla sells Cybercab to first private customers Reuters reports Tesla is offering its Cybercab to its first private customers. M impact | EQUITY | Nov 14, 2026, 04:23 AM UTC Microsoft says affected services fully recovered L impact | EQUITY | Nov 14, 2026, 04:14 AM UTC